SPC25 and prostate adenocarcinoma: SPC25 is significantly upregulated in PRAD tissues and cells, correlating with poor prognosis. It enhances cancer cell viability, promotes glycolysis, and inhibits ferroptosis. Overexpression of SPC25 increases extracellular acidification, glucose uptake, and lactate secretion, while suppressing oxygen consumption. 2-DG counteracts some of SPC25's effects, alleviating changes in ferroptosis markers.